Zenas BioPharma Grants 235,700 Stock Options and 33,450 RSUs at $23.23 Exercise Price
Zenas BioPharma’s Compensation Committee granted 235,700 ten-year stock options and 33,450 RSUs to new hires under Nasdaq Rule 5635(c)(4) on March 16, 2026. Options at $23.23 exercise price vest 25% after one year then monthly over 36 months, while RSUs vest in four annual installments.
1. Inducement Grants Details
On March 16, 2026, Zenas BioPharma’s Compensation Committee approved inducement grants under Nasdaq Rule 5635(c)(4) comprising 235,700 non-qualified stock options and 33,450 restricted stock units to newly hired employees as part of its 2026 Inducement Plan.
2. Stock Options Terms
The stock options carry a ten-year term with an exercise price of $23.23 per share, equal to the closing price on the grant date. Vesting occurs 25% after one year of service, with the remaining 75% vesting in 36 equal monthly installments.
3. RSUs Vesting Schedule
The 33,450 RSUs vest in four equal annual installments on March 15 of each year from 2027 through 2030, contingent on continued service through each vesting date.
4. Implications for Shareholder Equity
These inducement grants may lead to future share dilution as employees exercise options or receive vested RSUs, while also serving as a retention tool to attract experienced talent to advance Zenas’ clinical-stage pipeline.